Latest news on when Bosutinib will be officially launched in the country

As of2025, Bosutinib (Bosutinib) has not yet received marketing approval from the China National Medical Products Administration (NMPA), nor has it appeared in the latest round of the National Medical Insurance List. As a second-line and third-line targeted drug mainly used to treat chronic myelogenous leukemia (CML), especially for patients with resistance or intolerance to first-line TKI treatment, bosutinib has long been approved and widely used in European and American countries. Since there is no news of its launch in China, many patients and doctor groups are paying close attention to its approval status and clinical research progress in entering the Chinese market.

Currently, if domestic patients need to use bosutinib, they can only obtain it through cross-border drug purchase or overseas medical platforms. The overseas original version is developed by Pfizer (Pfizer) and is mainly marketed and circulated in the European Union, Japan, the United States and other regions. The specifications of the original medicine are usually 500mg*28 tablets, and a box sells for more than 30,000 yuan. The price is relatively high and the financial burden is not small. Some patients purchase drugs through Hong Kong or Southeast Asian countries, but they still have to bear higher costs and a longer drug purchase cycle.

Considering the higher cost of original drugs, some patients have turned to Indian generic versions. It is understood that Mylan (Mylan), a well-known generic drug company, has launched a generic version of bosutinib, whose dosage and efficacy are close to those of the original drug. The Indian version of 500mg*28 tablets costs about more than 1,000 yuan per box, less than one-twentieth of the original drug, significantly reducing economic pressure. Generic drugs have become an important medication choice for economical patient groups, but it is recommended that they be purchased through formal channels to ensure drug quality and therapeutic effect.

There is currently no official and clear public information on whether bosutinib will be officially launched in China in the next few years. However, as the market demand for TKI targeted drugs continues to increase, it is expected that their introduction and approval will be accelerated in the future. Prior to this, if patients need to use the drug, they should evaluate the efficacy and risks under the guidance of a professional doctor, and choose legal and compliant cross-border medical or pharmaceutical channels to obtain the drug. At the same time, you can also pay attention to the open information of relevant domestic clinical trials and strive to benefit from clinical drug opportunities in advance. While waiting for bosutinib to be officially launched, ensuring treatment continuity and drug safety are priorities that cannot be ignored in patient management.

Reference materials:https://www.drugs.com/